EPHB1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL374852	0.72	3/20
SCHEMBL374299	0.57	3/20
Infigratinib (SCHEMBL374435)	1.00	2/20
SCHEMBL2011033	0.91	2/20
SCHEMBL2013451	0.91	2/20
SCHEMBL2014363	0.84	2/20
SCHEMBL2017841	0.84	2/20
SCHEMBL374536	0.84	2/20
SCHEMBL583166	0.83	2/20
SCHEMBL2009510	0.83	2/20
SCHEMBL2014816	0.83	2/20
SCHEMBL2014529	0.81	2/20
SCHEMBL2015745	0.81	2/20
SCHEMBL2010818	0.80	2/20
SCHEMBL374149	0.80	2/20
SCHEMBL1446583	0.80	2/20
SCHEMBL2010460	0.79	2/20
SCHEMBL2011763	0.79	2/20
SCHEMBL2012965	0.79	2/20
SCHEMBL2010996	0.78	2/20

Clinical trials — most relevant to EPHB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	PHASE1/PHASE2	COMPLETED
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer	PHASE2	COMPLETED
Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer	PHASE1/PHASE2	COMPLETED
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC	PHASE1/PHASE2	UNKNOWN
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）	PHASE2	RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma	PHASE1	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Toxins Removal and Inflammatory State modulAtion During Online Hemodiafiltration: Comparison of Two Different Dialyzers	nan	UNKNOWN
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers	nan	RECRUITING
The Locus Coeruleus, Norepinephrine and Cognitive Aging	nan	ACTIVE_NOT_RECRUITING
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
The Role of Gene Changes in Brain Tumor Formation and Growth	nan	COMPLETED
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy.	nan	UNKNOWN
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury	nan	UNKNOWN
Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection	nan	NOT_YET_RECRUITING
Plant Sterol INtervention for Cancer Prevention (PINC)	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness	nan	UNKNOWN
European Registry of Acutely Decompensated Pulmonary Arterial Hypertension	nan	NOT_YET_RECRUITING
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a EPHB1 binder may also engage these)

Protein	Name	Similarity
Q8CBF3	—	1.000	Q8CBF3 →
Q90344	—	1.000	Q90344 →
P09759	—	1.000	P09759 →
Q07498	—	1.000	Q07498 →
Q91735	—	1.000	Q91735 →
Q07497	—	0.999	Q07497 →
Q60629	—	0.999	Q60629 →
Q91736	—	0.999	Q91736 →
Q91571	—	0.999	Q91571 →
EPHA3	Ephrin type-A receptor 3	0.998	landscape →
O42422	—	0.998	O42422 →
Q03145	—	0.998	Q03145 →
EPHA6	Ephrin type-A receptor 6	0.998	landscape →
EPHA5	Ephrin type-A receptor 5	0.998	landscape →
P54757	—	0.997	P54757 →
P54755	—	0.997	P54755 →
EPHB2	Ephrin type-B receptor 2	0.997	landscape →
P54763	—	0.997	P54763 →
Q62413	—	0.996	Q62413 →
EPHA4	Ephrin type-A receptor 4	0.996	landscape →
O08680	—	0.996	O08680 →
Q03137	—	0.996	Q03137 →
Q91694	—	0.995	Q91694 →
Q91845	—	0.995	Q91845 →
P28693	—	0.995	P28693 →
EPHB3	Ephrin type-B receptor 3	0.995	landscape →
P54754	—	0.994	P54754 →
EPHA7	Ephrin type-A receptor 7	0.994	landscape →
P54759	—	0.994	P54759 →
Q1KL86	—	0.994	Q1KL86 →